Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Current management options for recurrent adrenocortical carcinoma.Onco Targets Ther. 2013; 6: 635-643
- Metabolic and endocrine toxicities of mitotane: a systematic review.Cancers (Basel). 2021; 13: 5001
- Prognostic parameters of metastatic adrenocortical carcinoma.J Clin Endocrinol Metab. 2007; 92: 148-154
- American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach.Endocr Pract. 2020; 26: 1366-1383
- Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.J Am Coll Surg. 2016; 222 ([published correction appears in J Am Coll Surg. 2018 Jan;226(1):114]): 480-490
- Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients.J Endocr Soc. 2021; 5 (Published 2021 May 3): A166-A167
- Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE).Arch Pathol (Chic). 1949; 48: 387-394
- Chemotherapy of adrenocortical cancer with o,p′ddd.Ann Intern Med. 1960; 53: 672-682
- Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.Oncotarget. 2017; 8 (Published 2017 Jul 4): 109924-109940https://doi.org/10.18632/oncotarget.18968
- A peripheral action of o,p' -ddd on steroid biotransformation.J Clin Endocrinol Metab. 1963; 23: 918-922
- Effect of o,p'DDD on human adrenal steroid 11 beta-hydroxylation activity.J Clin Endocrinol Metab. 1973; 36: 730-733
- Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.Clin Endocrinol (Oxf). 2011; 75: 585-591
- First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: the adjuvo study.J Clin Oncol. 2022; 40: 1
- Role of mitotane in adrenocortical carcinoma - review and state of the art.Eur Endocrinol. 2018; 14: 62-66
- Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis.Biomed Res Int. 2018; 2018: 9362108
- Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 1476-1490
- The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.Biomedicines. 2021; 9: 98
- Combination chemotherapy in advanced adrenocortical carcinoma.N Engl J Med. 2012; 366: 2189-2197
- Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.Int J Clin Oncol. 2021; 26: 2275-2281
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.Eur J Endocrinol. 2012; 166: 451-458
- Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.J Clin Endocrinol Metab. 2012; 97: 3495-3503
- Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.Br J Cancer. 2013; 108: 1994-1997
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.Br J Cancer. 2013; 108: 826-830
- The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.J Clin Endocrinol Metab. 2014; 99: 1291-1297
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.Lancet Oncol. 2015; 16: 426-435https://doi.org/10.1016/S1470-2045(15)70081-1
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.J Immunother Cancer. 2018; 6: 111
- Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.J Immunother Cancer. 2019; 7: 253
- Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial.J Clin Endocrinol Metab. 2019; 104: 6193-6200
- PD-1 blockade in advanced adrenocortical carcinoma.J Clin Oncol. 2020; 38: 71-80
- American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.JAMA Surg. 2022; 157: 870-877
- Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.World J Surg. 2014; 38: 1318-1327
- Medical approaches in adrenocortical carcinoma.Biomedicines. 2020; 8: 551
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
